Announcement PDF | Page 1 ASX Announcement 10 June 2026 Cogstate Investor Webinar Materials Cogstate Ltd (ASX:CGS), will today host an investor webinar titled “Unlocking Sustainable Clinical Trials Growth through Indication and Solution Expansion” to update investors on the momentum and diversification of its Clinical Trials business. The webinar will be held on Wednesday, 10 June at 9.00am AEST (Tuesday, 9 June at 7.00pm US ET) and will focus on how Cogstate is growing the value of Clinical Trials sales contracts through indication expansion, which increases the size of the addressable market, and solution expansion, which increases the average contract value. Management will discuss key drivers of strong FY26 Clinical Trials sales contract growth, including growing contributions from Psychiatry and Narcolepsy and the role of services such as central rating to increase Cogstate average contract value. Presenters will include Cogstate executives and scientific leaders, who will provide market context and case studies on the application of Cogstate’s cognitive and related clinical outcome solutions in narcolepsy and psychiatry trials. The session will also address how diversification by indication and the expansion of high-value services are supporting sustained growth into FY27 and beyond. A copy of the presentation materials is attached. Participants can register at https://investors.cogstate.com/webinars/mPq8pr-unlocking-sustainable-clinical-trials- growth This announcement was authorised for release by the CEO of Cogstate Ltd. For further information contact: investor@cogstate.com About Cogstate Cogstate Ltd (ASX: CGS) is a global Central Nervous System (CNS) endpoint innovations company that partners with drug developers to power complex neuroscience studies. Cogstate uniquely specializes in the science and service of CNS measurement to ensure clinical trial endpoint data is as accurate as it is actionable. Our applied technology solutions include fit-for-purpose data quality programs, advanced analytics, and digital cognitive testing to identify clear signals for confident decision-making. Building upon 25 years of customized collaborations, Cogstate is accelerating the next generation of CNS therapies. In the Healthcare market, Cogstate seeks to provide primary care physicians and consumers with brief, accurate and scientifically validated digital measures of cognition, with a focus on easy to use, self-administered tests that inform patients and save physician time. For more information, please visit www.cogstate.com. | Page 2 Important Notices Past performance Past performance is given for illustrative purposes only and should not be relied upon as (and is not) an indication of Cogstate's views on its future financial performance or condition. Past performance of Cogstate cannot be relied upon as an indicator of (and provides no guidance as to) the future performance of Cogstate. Nothing contained in this announcement, nor any information made available to you is, or shall be relied upon as, a promise, representation, warranty, or guarantee, whether as to the past, present, or future. Future performance and forward-looking statements This announcement contains certain “forward-looking statements.” The words “expect,” “anticipate,” “estimate”, “intend”, “believe”, “guidance”, “should”, “could”, “may”, “will”, “predict”, “plan” and other similar expressions are intended to identify forward-looking statements. Indications of, and guidance on, future earnings and financial position and performance are also forward-looking statements. Forward-looking statements, opinions and estimates provided in this announcement are based on assumptions and contingencies that are subject to change without notice and involve known and unknown risks and uncertainties and other factors that are beyond the control of Cogstate, its directors and management. Forward-looking statements are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance. Actual results, performance or achievements may differ materially from those expressed or implied in such statements and any projections and assumptions on which these statements are based. These statements may assume the success of Cogstate's business strategies, including the fact that the results of any of those strategies will be realised in the period for which the forward-looking statement may have been prepared or otherwise. For example, Cogstate's performance in any one financial period is sensitive to whether or not contracts are signed in that period, or a subsequent period, and the rate of enrolment in trials of its customers, which are influenced by factors that are outside of Cogstate's control. Readers are cautioned not to place undue reliance on forward-looking statements and except as required by law or regulations, none of Cogstate, its representatives or advisers, assumes any obligation to update these forward- looking statements. No representation or warranty, express or implied, is made as to the accuracy, likelihood of achievement or reasonableness of any forecasts, prospects, returns or statements in relation to future matters contained in this announcement. The forward-looking statements are based on information available to Cogstate as at the date of this announcement. Except as required by law or regulation (including the ASX Listing Rules), none of Cogstate, its representatives or advisers undertakes any obligation to provide any additional or updated information, whether as a result of a change in expectations or assumptions, new information, future events or results or otherwise. Indications of, and guidance or outlook on, future earnings or financial position or performance are also forward-looking statements. © 2026 Cogstate Ltd. All rights reserved. Unlocking Sustainable Clinical Trials Growth Through Indication & Solution Expansion Investor Webinar | 10 June 2026 2 Sales Contracts Reflecting Greater Diversification 0 10 20 30 40 50 60 70 80 90 FY22 FY23 FY24 FY25 FY26 (9 months) US$ Millions 9 months to 31-Mar-26: $67.1m sales contracts executed Alzheimer’s Mood, Sleep & Other Neurological Rare Cancer Metabolic & Other Mood, Sleep & Other Neurological 35% Alzheimer’s 47% Cancer Metabolic & Other 4% Rare Diseases 14% 3 Offering Cogstate services at scale Strategic Technology Partners and Integrations 3 4 Pipeline Expansion Tracking to Sales Conversion 0 20 40 60 80 100 120 140 160 180 1H FY16 2H FY16 1H FY17 2H FY17 1H FY18 2H FY18 1H FY19 2H FY19 1H FY20 2H FY20 1H FY21 2H FY21 1H FY22 2H FY22 1H FY23 2H FY23 1H FY24 2H FY24 1H FY25 2H FY25 1H FY26 Number of New Opportunities Number of New Contracts 5 The electronic data capture systems are optimized to reduce error The clinicians are trained and monitored to deliver assessments correctly, regardless of geography or language The right assessments are used Cogstate ensures Why our Customers Choose Us For more than 20 years we’ve built long-term relationships with major pharmaceutical companies “ ” 6 Central Rating: A Key Growth Lever 6 Embedded within the trial workflows Expands Cogstate’s role in the trial delivery Enables broader engagement across programs Expanding the solution set • Adds high-value services to trials • Improves consistency and quality of clinical data • Complementary to existing assessment solutions Drives Deeper Customer Relationships 7 Validated digital assessments Science-led and scalable training + monitoring + rating Strong sponsor relationships Why We're Winning in New Indications 7 eCOA partner ecosystem 8 9 Market Context: Narcolepsy (NT) and Orexin Clinical trials in Sleep/wake disorders expanding at ~8–12% annually, driven by promising data from orexin-based pharmacotherapies, increased disease awareness, and technology-enabled trials • Orexin therapies represent a disease-targeted shift – Novel: Role in NT discovered in 2000 – Orexin 2 agonists restore wake-promoting signaling, addressing the underlying biology of NT1 (2023 US prevalence, 12.6 per 100,000) – Strong safety data – Pipeline expansion across NT1, NT2, and idiopathic hypersomnia is increasing both asset count and trial activity • Modulalation of Orexin neurotransmission has direct and indirect effects on cognition – Neurological, neurodegenerative, and neuropsychiatric conditions • Orexin expansion beyond sleep/wake creates incremental parallel trials per asset – Neurological, neurodegenerative, and neuropsychiatric conditions (extends needs for Cogstate services and tech) • Greater use of tech-enabled and home-based models – Wearables, remote monitoring, and home sleep studies are expanding access • Regulatory momentum for novel mechanisms – Priority reviews and breakthrough designations for orexin therapies are accelerating timelines and trial activity 10 Oveporexton (TAK-861) first in class orexin agonist improves cognition in NT1 Lammers et al JAMA Neurol 2026 Move to phase III 40th Annual Meeting of the Associated Professional Sleep Societies Baltimore June 2026 Move to FDA approval & marketing Figure. Oveporexton Effect Size on Cognitive Measures (Cohen d) 11 Wide therapeutic potential for modulation of orexin neurotransmission beyond sleep/wake disorders Disorders characterized by loss of cholinergic or catecholaminergic input to the cortex. Neurodegenerative disorders Disorders characterized by sleepiness or fatigue symptoms, (MS, PD) Sleep/wake disorders (NT1, IH) Disorders characterized by problems of mood or adaptive behavior. (MDD, schizophrenia) 12 Market Context: Psychiatry Psychiatry trials are expanding at ~8-10% annually, reflecting renewed CNS investment and increasing global disease burden • Pipeline diversification through new mechanisms and digital therapeutics • Psychedelics (e.g., psilocybin, MDMA, ketamine, DMT) represent a different neurobiological approach targeting high unmet need segments (TRD, PTSD, addiction) • GLP-1 receptor agonists are now being evaluated in psychiatric and neurobehavioral conditions (e.g., depression, addiction, cognitive impairment, and neurodegeneration) • These diversifications are driving factors in the change endpoint assessments are employed (e.g., blinded raters, compressed assessment periods) • Greater use of decentralized / tech-enabled trial models (Cogstate Central Rating) • Regulatory tailwinds and funding for innovative therapies and adaptive trial designs 13 Cogstate in Psychiatry Clinical Trials Our approach is grounded in a distinctive training philosophy that treats endpoint scales as structured systems with an internal logic, rather than as symptom checklists or collections of isolated scoring rules. Across rater training, data monitoring, and central rater calibration, we help raters understand how items are differentiated, constrained, and related, with the aim of improving the coherence and reliability of ratings and reducing Type II placebo response. Structuralist Approach 14 Scaling the Delivery Model with AI Technology-enabled Operations Combination of clinical expertise and technology Increasing standardization and automation Supports growth without linear cost increase 15 Strong FY26 momentum driven by more trials + broader mix + high value per trial Sales Momentum Diversification Solution Expansion 1 2 3 Diversification beyond Alzheimer’s into Psychiatry, Narcolepsy/Orexin, Rare – and across multiple large pharma preferred relationships Expansion of solutions increasing revenue per contract and share of wallet 15 Summary Positioned for sustained growth into FY27 and beyond 16 Cogstate Investor Insights Series Upcoming Events Quarterly: Cogstate 4Q26 Sales Contracts, incl. FY27 revenue under contract at 01-Jul-26 Wednesday 08th July 2026, pre-market open Webinar: Cogstate Full Year FY26 Results Tuesday 18th August 2026,12.00pm AEST Quarterly: Cogstate 1Q27 Sales Contracts Monday 12th October 2026, pre-market open Annual General Meeting of Shareholders Thursday 15th October 2026,10am (virtual and in person – Melbourne)